Literature DB >> 17548437

JC virus in cerebrospinal fluid samples of multiple sclerosis patients at the first demyelinating event.

Roberto Alvarez-Lafuente1, Marta García-Montojo, Virginia De Las Heras, Manuel Bartolomé, Rafael Arroyo.   

Abstract

OBJECTIVE: To evaluate the possible involvement of JC virus (JCV) in the aetiology of multiple sclerosis (MS), through the comparison of DNA prevalences and viral loads of JCV in cerebrospinal fluid (CSF) of MS patients at the first demyelinating event and subjects suffering from other neurological diseases (OND).
METHODS: Seventy-three CSF samples (43 from MS patients at the first demyelinating event, and 30 from patients with OND) were collected; all MS cases were followed up from 1 to 6.7 years after they were diagnosed with clinically definite MS. DNA was extracted and analysed by real-time PCR for the detection of JCV genomes.
RESULTS: We found JCV DNA in the CSF of two MS patients (4.7%) with a mean viral load of 2.1 and 6.7 copies/mL of CSF. Among the patients of the OND group we did not find any positive sample. We did not find any difference in the course of the disease between MS patients with and without JCV genomes in their CSF along the follow up.
CONCLUSION: JCV seems to be only a bystander in the pathology of MS, and the presence of cell-free viral particles could be related to the immunological activation of the disease, mainly during relapses.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17548437     DOI: 10.1177/1352458506073116

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  15 in total

1.  JC virus reactivation during prolonged natalizumab monotherapy for multiple sclerosis.

Authors:  Spyridon Chalkias; Xin Dang; Evelyn Bord; Marion C Stein; R Philip Kinkel; Jacob A Sloane; Maureen Donnelly; Carolina Ionete; Maria K Houtchens; Guy J Buckle; Stephanie Batson; Igor J Koralnik
Journal:  Ann Neurol       Date:  2014-06-10       Impact factor: 10.422

2.  Analysis of cerebrospinal fluid and cerebrospinal fluid cells from patients with multiple sclerosis for detection of JC virus DNA.

Authors:  E Iacobaeus; C Ryschkewitsch; M Gravell; M Khademi; E Wallstrom; T Olsson; L Brundin; Eo Major
Journal:  Mult Scler       Date:  2008-09-19       Impact factor: 6.312

Review 3.  Diagnosis and Treatment of Progressive Multifocal Leukoencephalopathy Associated with Multiple Sclerosis Therapies.

Authors:  Eric M L Williamson; Joseph R Berger
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

4.  JC virus infection of meningeal and choroid plexus cells in patients with progressive multifocal leukoencephalopathy.

Authors:  Sarah M Corbridge; Richard C Rice; Linda A Bean; Christian Wüthrich; Xin Dang; Daniel A Nicholson; Igor J Koralnik
Journal:  J Neurovirol       Date:  2019-04-25       Impact factor: 2.643

Review 5.  Progressive multifocal leukoencephalopathy and other forms of JC virus disease.

Authors:  Bruce J Brew; Nicholas W S Davies; Paola Cinque; David B Clifford; Avindra Nath
Journal:  Nat Rev Neurol       Date:  2010-12       Impact factor: 42.937

6.  JCV detection in multiple sclerosis patients treated with natalizumab.

Authors:  Saud A Sadiq; Lauren M Puccio; Edward W A Brydon
Journal:  J Neurol       Date:  2010-01-07       Impact factor: 4.849

Review 7.  [Progressive multifocal leukoencephalopathy. Undesirable side effect of immunotherapy].

Authors:  H-P Hartung; C Warnke; R Hohlfeld; B C Kieseier
Journal:  Nervenarzt       Date:  2009-10       Impact factor: 1.214

Review 8.  Classification of HHV-6A and HHV-6B as distinct viruses.

Authors:  Dharam Ablashi; Henri Agut; Roberto Alvarez-Lafuente; Duncan A Clark; Stephen Dewhurst; Dario DiLuca; Louis Flamand; Niza Frenkel; Robert Gallo; Ursula A Gompels; Per Höllsberg; Steven Jacobson; Mario Luppi; Paolo Lusso; Mauro Malnati; Peter Medveczky; Yasuko Mori; Philip E Pellett; Joshua C Pritchett; Koichi Yamanishi; Tetsushi Yoshikawa
Journal:  Arch Virol       Date:  2013-11-06       Impact factor: 2.574

Review 9.  Update on PML: lessons from the HIV uninfected and new insights in pathogenesis and treatment.

Authors:  Elizabeth A Hartman; DeRen Huang
Journal:  Curr HIV/AIDS Rep       Date:  2008-08       Impact factor: 5.071

10.  May New Biomarkers Help us to Predict Progressive Multifocal Leukoencephalopathy in HIV Positive People?

Authors:  Zohreh Aminzadeh
Journal:  Int J Prev Med       Date:  2012-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.